Verubecestat, a brain-penetrant small molecule BACE1 inhibitor, may have even accelerated cognitive decline in patients despite its robust effects on AD biomarkers [139], possibly ending one of the most ardently pursued investigational avenues into a therapy for AD. Here, BACE1 is linked to Alzheimer disease.